ISSN: 1859 - 2872
The relationship of plasma asymmetric dimethylarginine level with cardiovascular risk factors in end-stage renal disease patients prior kidney transplant
Main Article Content
Keywords
Abstract
Objective: To survey on plasma asymmetric dimethylarginine and relationship with some cardiovascular risk factors in end-stage renal disease patients who were indicated kidney transplantation. Subject and method: A controlled cross-sectional study in 112 end-stage renal disease (ESRD) patients who have indication kidney transplantation and 80 controlled healthy people at 103 Military Hospital from March 2018 to April 2020. Result: The median concentration of plasma ADMA in the patient group: 0.62µmol/l was higher than the control group: 0.17µmol/l with p<0.001. There were 98.2% of patients increased plasma ADMA. ADMA levels were higher in patients with dyslipidemia and high Atherogenic Index of Plasma (AIP), (p<0.05). The variables found to be positively correlated with ADMA levels were AIP, cholesterol and left atrial diameter, r = 0.493, p<0.001 Conclusion: Elevated plasma ADMA concentrations are common and correlated with AIP, cholesterol, and left atrial diameter in ESRD patients prior kidney transplant.
Article Details
References
2. Yuan J, Zou XR, Han SP et al (2017) Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol 18(1): 23. doi: 10.1186/s12882-017-0441-9.
3. Gopu CL, Haria PR, George R et al (2013) Simultaneous determination of homocysteine and asymmetric dimethylarginine in human urine by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 939: 32-37.
4. Liu X, Xu X, Shang R, Chen Y (2018) Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease. Nitric Oxide 78: 113-120.
5. Dobrian AD, (2012) ADMA and NOS regulation in chronic renal disease: beyond the old rivalry for l-arginine. Kidney Int 81(8): 722-724.
6. Abedini S et al (2010) Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 77(1): 44-50.
7. Hoàng Trọng Ái Quốc, V.T., Hoàng Viết Thắng (2016) Nghiên cứu nồng độ asymetric dimethylarginine huyết tương và mối liên quan với một số yếu tố nguy cơ tim mạch ở bệnh nhân bệnh thận mạn giai đoạn cuối. Tạp chí Y Dược học- Trường Đại học Y dược Huế, 2015. Tập 6 (02) - Số 32/2016; tr. 51.
8. Nguyễn Hữu Thịnh, N.T.T.H., Hoàng Bùi Bảo (2014) Khảo sát một số yếu tố nguy cơ tim mạch và bất thường điện tim, siêu âm tim ở bệnh nhân đang chờ ghép thận. Tại chí Y Dược học.
9. Said MY, Douwes RM, van Londen M et al (2019) Effect of renal function on homeostasis of asymmetric dimethylarginine (ADMA): Studies in donors and recipients of renal transplants. Amino Acids 51(3): 565-575. doi: 10.1007/s00726-018-02693-z.
10. Eiselt J, Rajdl D, Racek J et al (2014) Asymmetric dimethylarginine and progression of chronic kidney disease: A one-year follow-up study. Kidney Blood Press Res 39(1): 50-57. doi: 10.1159/000355776.
11. Lu TM, Chung MY, Lin CC et al (2011) Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 6(7): 1566-1572. doi: 10.2215/CJN.08490910.
Article Sidebar
